^
No biomarker
|
Mediastinal B Cell Lymphoma
|
No biomarker
|
Mediastinal B Cell Lymphoma
|
axicabtagene ciloleucel Sensitive: A1 - Approval
|
axicabtagene ciloleucel Sensitive: A1 - Approval
|
No biomarker
|
Mediastinal B Cell Lymphoma
|
No biomarker
|
Mediastinal B Cell Lymphoma
|
pembrolizumab Sensitive: A1 - Approval
|
pembrolizumab Sensitive: A1 - Approval
|
No biomarker
|
Mediastinal B Cell Lymphoma
|
No biomarker
|
Mediastinal B Cell Lymphoma
|
lisocabtagene maraleucel Sensitive: A1 - Approval
|
lisocabtagene maraleucel Sensitive: A1 - Approval
|
No biomarker
|
Mediastinal B Cell Lymphoma
|
No biomarker
|
Mediastinal B Cell Lymphoma
|
rituximab Sensitive: A2 - Guideline
|
rituximab Sensitive: A2 - Guideline
|
MYC overexpression
|
Mediastinal B Cell Lymphoma
|
MYC overexpression
|
Mediastinal B Cell Lymphoma
|
lisocabtagene maraleucel Resistant: C3 – Early Trials
|
lisocabtagene maraleucel Resistant: C3 – Early Trials
|
EZH2 overexpression
|
Mediastinal B Cell Lymphoma
|
EZH2 overexpression
|
Mediastinal B Cell Lymphoma
|
lisocabtagene maraleucel Resistant: C3 – Early Trials
|
lisocabtagene maraleucel Resistant: C3 – Early Trials
|
MYC rearrangement
|
Mediastinal B Cell Lymphoma
|
MYC rearrangement
|
Mediastinal B Cell Lymphoma
|
rituximab Sensitive: C3 – Early Trials
|
rituximab Sensitive: C3 – Early Trials
|
BCL6 rearrangement
|
Mediastinal B Cell Lymphoma
|
BCL6 rearrangement
|
Mediastinal B Cell Lymphoma
|
rituximab Sensitive: C3 – Early Trials
|
rituximab Sensitive: C3 – Early Trials
|
